•The American Society of Breast Surgeons (ASBrS) updated its 2026 Resource Guide to recommend cryoablation as an option for low-risk early-stage breast cancer patients.
•The recommendation is based on IceCure's ICE3 study results and a favorable FDA Advisory Panel vote.
•The update is expected to accelerate commercial adoption of IceCure Medical's ProSense technology following FDA clearance.
